COMMUNIQUÉS West-GlobeNewswire

Coloplast A/S - Interim Financial Report, Q1 2023/24
09/02/2024
Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin 1) of 28%. Reported revenue in DKK grew 8% with 4%-points [...]
KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share
09/02/2024
EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people [...]
IBA acquires Radcal Corporation to expand Medical Imaging Quality Assurance offering and strengthen US presence
09/02/2024
Highly complementary acquisition continues IBA’s expansion strategy to lead the Radiotherapy, Medical Imaging Dosimetry and Quality Assurance markets globally Louvain-la-Neuve, Belgium, February 9, 2024 – IBA (Ion Beam [...]
IBA acquiert Radcal Corporation afin d’élargir son offre d'assurance qualité en imagerie médicale et renforcer sa présence aux États-Unis.
09/02/2024
Acquisition complémentaire en vue de poursuivre la stratégie d'expansion d’IBA pour devenir le leader mondial du marché de l’assurance qualité en radiothérapie et en imagerie médicale. Louvain-la-Neuve, Belgique, le 9 [...]
Metagenomi Announces Pricing of Initial Public Offering
09/02/2024
EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary [...]
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
08/02/2024
AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and [...]
Telomir Pharmaceuticals Announces Pricing of Initial Public Offering
08/02/2024
BALTIMORE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, is developing Telomir-1 as the first [...]
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08/02/2024
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and [...]
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/02/2024
EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the [...]
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
08/02/2024
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15, 2024, after the close [...]
Surgery Partners, Inc. Announces Fourth Quarter 2023 Earnings Release Date and Conference Call Details
08/02/2024
BRENTWOOD, Tenn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will [...]
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
08/02/2024
Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditions Introduces recurring revenue model for the SRT-100 Vision ™ (IG-SRT) to address [...]
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
08/02/2024
MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the fourth quarter and [...]
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
08/02/2024
MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a corporate update on [...]
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
08/02/2024
CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
08/02/2024
BRIDGEWATER, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmission to the U.S. Food and [...]
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
08/02/2024
Company on track to initiate soquelitinib Phase 3 registrational clinical trial in PTCL BURLINGAME, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage [...]
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
08/02/2024
Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS BOTHELL, Wash., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA [...]
BioXcel Therapeutics Announces Proposed Public Offering
08/02/2024
NEW HAVEN, Conn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines [...]

Pages